Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022
Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million
Significantly Increased Trading Liquidity with Recent Successful Secondary Offering
biote Corp. (Nasdaq: BTMD) ("Biote" or the "Company"), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced its participation in the
10.10.2022 - biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today released a new Corporate Presentation, which the Company may use from time to time .